Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.

Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precis Oncol. 2025 Jun; 9:e2400776.

View in: PubMed

subject areas

Adult
Aged
Breast Neoplasms
Female
Humans
Immunotherapy
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Receptors, Estrogen
Receptors, Progesterone

authors with profiles

Rita Nanda